Kamada (KMDA) Income from Continuing Operations (2012 - 2026)
Kamada (KMDA) reported Income from Continuing Operations of 4132000.0 for Q1 2026, down 55.39% on a YoY basis from 9262000.0 in Q1 2025, and down 30.04% quarter-over-quarter from 5906000.0 in Q4 2025.
Kamada (KMDA) Income from Continuing Operations (2012 - 2026) Analysis & Trends
Kamada has reported Income from Continuing Operations for 15 years, with the latest figure at 4132000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 55.39% year-over-year to 4132000.0; the trailing twelve-month figure through Mar 2026 stood at 18487130.0 (up 8.48% YoY), and the FY2025 full-year result was 26736000.0, up 119.04% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 4132000.0, down from 5906000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 9262000.0 in Q1 2025, with the low at 3921000.0 in Q2 2022.
- Historically, Income from Continuing Operations has averaged 2696929.41 across 5 years, with a median of 2944000.0 in 2022.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations slumped 518.46% — and 2024, when it surged 139016.53%.
- Kamada's Income from Continuing Operations stood at 2944000.0 in 2022, then jumped by 71.81% to 5058000.0 in 2023, then dropped by 24.71% to 3808000.0 in 2024, then jumped by 55.09% to 5906000.0 in 2025, then tumbled by 30.04% to 4132000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 4132000.0 (Q1 2026), 5906000.0 (Q4 2025), and 8445000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 370.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 601.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 274.90 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 21.05 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 197.90 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 57.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -66.53 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -92.12 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 118.42 Mn |
| 10 | Kamada | 504.70 | -73.15 Mn | 19.12 Mn | 4.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.13 Mn |
| Dec 31, 2025 | 5.91 Mn |
| Sep 30, 2025 | 8.45 Mn |
| Jun 30, 2025 | 4,130.00 |
| Mar 31, 2025 | 9.26 Mn |
| Dec 31, 2024 | 3.81 Mn |
| Sep 30, 2024 | 4.03 Mn |
| Jun 30, 2024 | -58,511.00 |
| Mar 31, 2024 | 2.51 Mn |
| Dec 31, 2023 | 5.06 Mn |
| Sep 30, 2023 | 3.22 Mn |
| Jun 30, 2023 | 1.84 Mn |
| Mar 31, 2023 | -1,809.00 |
| Dec 31, 2022 | 2.94 Mn |
| Sep 30, 2022 | 493,990.00 |
| Jun 30, 2022 | -3.92 Mn |
| Mar 31, 2022 | -1.83 Mn |
| Dec 31, 2021 | -4.66 Mn |
| Sep 30, 2021 | -845,000.00 |
| Jun 30, 2021 | 937,000.00 |